Skip to NavigationSkip to content

Boris Johnson

Election Day 2019: Where do the two frontrunners stand on the NHS?

The UK goes to the polls today, for the fourth election of the decade and the third since 2015.

Despite the election being initially called by Prime Minister Boris Johnson to break the parliamentary gridlock over Brexit, Labour Party leader Jeremy Corbyn has forced the main electoral issue to centre around the future of the National Health Service. Both have made significantly different proposals for the NHS’s future.

Jeremy Corbyn writes Trump letter asking for reassurance over NHS in trade deal

Labour Party leader Jeremy Corbyn has written to US President Donald Trump demanding he confirm that he will not put up drug prices in a UK-US post-Brexit trade deal.

Top Ten most popular articles on Pharmafile.com this week

The NHS was featured heavily in the news this week. Jeremy Corbyn revealed documents detailing previous UK-US discussions in which opening up the NHS to US drug firms were brought up. A report was also released this week showing that the majority of British people are concerned about the fate of the NHS due to the US trade deal; however this survey was conducted before this week’s revelations.

Majority of British people worried about the fate of the NHS in post-Brexit US trade deal, survey reveals

In a newly released survey on “Over-The-Counter (OTC) and Pharma 2019”, by the business data platform Statista, 55% of people surveyed were concerned about the potential post-Brexit trade deal with the US and its impact on the NHS.

The survey assessed the responses of more than 2,000 British consumers. The NHS being part of a UK-US trade deal was first touted back in June by US Ambassador to the UK, Woody Johnson.

Conservatives pledge to invest in preventing and curing disease in election manifesto

Prime Minister Boris Johnson launched the Conservative Party’s manifesto on Sunday, promising to invest more into research to prevent and cure diseases such as cancer and dementia.

The manifesto states it will improve ‘‘the early diagnosis and treatment of all major conditions’’ and the party will be ‘‘developing new treatments for serious disease.’’ Specifically, they plan to double the funding for research into dementia.

Mayor of London calls for dementia R&D centre

Boris image
Boris Johnson

The mayor of London Boris Johnson is calling on both the government and the private sector to come together and fund an International Dementia Research Institute to be based in England’s capital.

Johnson is hosting a meeting today with a number of pharma companies and charities, including GlaxoSmithKline, Lilly, Eisai, Alzheimer’s Research UK and Alzheimer’s Society at City Hall to support the concept of an International Dementia Research Institute.

Dr Eliot Forster to lead MedCity

Published on: 08/04/14

Dr Eliot Forster has been appointed chairman of MedCity Limited by the London mayor Boris Johnson.

Dr Forster has 20 years of industry experience in biotechnology and pharmaceutical companies. He was most recently the chief executive of Solace Pharmaceuticals, a US-based biotech, before becoming chief executive of European biotech Creabilis.

Prior joining Solace, Dr Forster was Head of EU development and of development operations in the EU & Asia at Pfizer.

MedCity will be ‘concierge’ for life sciences

London mayor Boris Johnson launches MedCity

MedCity, the new entity seeking to capitalise on the so-called ‘golden triangle’ of medical and life sciences R&D organisations between London, Oxford and Cambridge, has been officially launched.

The idea is to bring together parties that can help with the discovery and commercialisation of new drugs to tackle diseases such as dementia, diabetes and cancer, whilst also attracting major life science corporations to locate to the three cities and assist small companies to spin out of academia.

MedCity to launch in April

Boris image

The eagerly anticipated launch of ‘MedCity’ will be announced in April, Pharmafile has learned, as the UK government looks to bring its big three cities of science closer together. 

Set to be launched by London mayor Boris Johnson on 8 April, the capital is looking to create a ‘golden triangle’ in medical and life sciences research, linking London with Oxford and Cambridge.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches